Ocular Rosacea

Proposed Mechanisms

• Vascular dysfunction: Aberrant vasodilation and increased vascular permeability driven by upregulation of VEGF-A, promoting telangiectasia and lymphangiogenesis at the lid margin and conjunctiva
• Innate immune activation: Elevated IL-6, IL-8, TNF-α, and TLR-2 expression; cathelicidin antimicrobial peptides (LL-37) are overproduced via KLK5 (kallikrein-5) and KLK7 serine protease cleavage, activating mast cells and keratinocytes and amplifying the inflammatory signalling cascade
• LL-37 / Cathelicidin pathway: KLK5 proteolytically cleaves cathelicidin precursors to active LL-37; LL-37 binds TLR-2, triggering NF-κB activation, VEGF release, and neutrophil recruitment — central to rosacea pathophysiology
• Demodex mite dysbiosis: Demodex folliculorum colonises lash follicles; D. brevis inhabits meibomian glands. Overpopulation (>5 mites/cm²) triggers immune response; Bacillus oleronius, an endosymbiont of Demodex, acts as a further immune stimulator via TLR-2 signalling
• Neurogenic inflammation: Trigeminal nerve hyperresponsiveness with substance P and CGRP release; neuropeptide-mediated vasodilation exacerbates vascular instability and flushing; TRPV1 and TRPA1 nociceptors on sensory nerve fibres are sensitised by heat, capsaicin, and oxidative stress
• Photo-oxidative stress: Chronic UV exposure promotes reactive oxygen species (ROS) generation, upregulating MMP-1, MMP-2, and VEGF in dermal fibroblasts and ocular surface epithelium, accelerating structural damage

Genetic Predisposition

• Genome-wide association studies (GWAS) have identified associations with HLA-DRA and HLA-DQB1 alleles, implicating adaptive immune dysregulation as a contributing factor
• Polymorphisms in genes encoding VEGF, TLR-2, and kallikrein serine proteases (KLK5, KLK7) have been reported in rosacea cohorts
• Strong familial clustering observed; first-degree relatives of rosacea patients have approximately 4× increased risk compared to the general population
• Prevalence markedly higher in Fitzpatrick skin types I–II (Celtic, Northern European, Scandinavian descent); lower reported prevalence in Asian and African populations, though this may partly reflect underdiagnosis due to less visible erythema on darker skin

Relationship to Cutaneous Rosacea

Ocular involvement occurs in 6–72% of patients with cutaneous rosacea, depending on diagnostic criteria and study population. Cutaneous rosacea precedes or co-occurs with ocular rosacea in the majority of cases, but ocular disease can be clinically isolated — importantly, ocular rosacea may precede or present without any skin findings in up to 20% of cases. Ocular severity does not reliably correlate with cutaneous disease severity, emphasising the importance of independent ocular assessment.

Inflammatory Cascade

1. Trigger activation: Environmental (heat, UV, wind), emotional (stress, embarrassment), or dietary factors (capsaicin, alcohol, hot beverages) activate TRPV1 and TRPA1 nociceptors in trigeminal sensory fibres, initiating the cascade
2. Neurogenic component: Trigeminal nerve hyperresponsiveness with substance P and CGRP release; neuropeptide-driven vasodilation and plasma extravasation amplify the local inflammatory milieu; mast cells degranulate in response, releasing histamine, prostaglandins, and additional pro-inflammatory cytokines
3. Innate immune cascade: TLR-2 activation by Demodex components or Bacillus oleronius; LL-37 overproduction drives IL-1β, IL-6, IL-8, TNF-α release; NF-κB activation perpetuates endothelial dysfunction and VEGF-A upregulation
4. Matrix metalloproteinase (MMP) upregulation: MMP-2 and MMP-9 are significantly elevated in the tears and conjunctival tissue of rosacea patients; MMPs degrade basement membrane and tight junctions (ZO-1, occludin), disrupting the ocular surface epithelial barrier and increasing corneal vulnerability to environmental insults
5. Meibomian gland involvement: Altered lipid composition — increased saturated fatty acids (palmitate, stearate) and reduced unsaturated lipids (oleate) — elevates meibum viscosity, causing obstructive MGD; the resulting hyperosmolar, lipid-deficient tear film is itself pro-inflammatory, perpetuating the cycle
6. Chronic inflammation and structural remodelling: Persistent conjunctival injection, telangiectasia formation, goblet cell loss, squamous metaplasia of the conjunctival epithelium, and progressive meibomian gland atrophy with irreversible glandular dropout

Ocular Surface Impact

Chronic inflammation leads to a cascade of structural and functional changes:

• Tear film instability and lipid layer deficiency: Evaporative dry eye dominates the phenotype; TBUT typically <5 s in moderate–severe disease; lipid layer grade reduced on interferometry
• Goblet cell loss: Secondary mucin deficiency (MUC5AC reduction) compounds aqueous layer instability; detectable by impression cytology and conjunctival lissamine green staining
• Increased corneal permeability and epithelial fragility: MMP-mediated breakdown of epithelial tight junctions; punctate epithelial erosions develop predominantly in the inferior interpalpebral zone
• Meibomian gland atrophy: Irreversible end-stage MGD with glandular dropout visible on infrared meibography; severity correlates with disease chronicity and duration
• Corneal infiltration and neovascularisation: Peripheral and inferior corneal vascularisation in severe disease; VEGF-A and IL-1β drive the limbal angiogenic response
• Recurrent epithelial erosions and keratitis: Progressive corneal disease resulting from combined lipid layer failure, MMP-driven barrier disruption, and secondary Staphylococcal colonisation

Kazin Classification (Severity Grading)

• Grade 1 (Mild): Conjunctival injection and telangiectasia; minimal lid margin involvement
• Grade 2 (Moderate): Anterior blepharitis, MGD, corneal infiltrates or epithelial erosions
• Grade 3 (Severe): Keratitis with scarring, neovascularization, or chronic epithelial defects
• Grade 4 (Very Severe): Structural changes, corneal thinning, or vision-threatening disease

Phenotypic Classification

• Anterior blepharitis-dominant: Lid margin and meibomian gland disease
• Conjunctival-dominant: Injection, telangiectasia, with minimal lid involvement
• Keratitis-dominant: Corneal infiltration and epithelial disease
• Mixed phenotype: Combination of the above

Demographic & Genetic

• Age 30-60 years (onset typically middle-aged)
• Female predominance (3:1 ratio)
• Fair skin (Celtic or Northern European descent)
• Personal or family history of cutaneous rosacea
• Genetic predisposition (familial clustering observed)

Environmental & Lifestyle Triggers

• Chronic sun exposure and UV radiation
• Extreme temperatures (hot, cold, wind)
• Stress and emotional triggers
• Spicy foods and hot beverages
• Alcohol consumption
• Vasodilating medications (topical corticosteroid withdrawal)

Associated Conditions

• Cutaneous rosacea (present in 50-90% of ocular rosacea patients)
• Meibomian gland dysfunction
• Dry eye disease (comorbid in >90% of cases)
• Seborrheic dermatitis

Eyelid Signs

• Lid margin erythema and edema — often bilateral, worse on upper lids
• Lid margin telangiectasia: Fine, dilated capillaries along posterior lid margin; best viewed at 16× slit-lamp magnification with diffuse illumination; characteristic of rosacea (vs seborrheic blepharitis)
• Meibomian gland orifice changes: Plugging (inspissated meibum forming "pearl" plugs), pouting (raised orifices), or retrograde flow of viscous or paste-like meibum on expression
• Meibum quality grading on expression: Grade 0 = clear fluid; Grade 1 = cloudy; Grade 2 = granular; Grade 3 = inspissated/no flow — Grades 2–3 typical in rosacea-associated MGD
• Anterior blepharitis with fine, collarette-type or misdirected lash scales
• Lid margin vascular injection extending posteriorly to the mucocutaneous junction

Conjunctival & Episcleral Signs

• Diffuse conjunctival injection predominating in the interpalpebral zone; worsens with environmental triggers and throughout the day
• Episcleral telangiectasia: Fine, serpentine dilated vessels visible on the bulbar conjunctiva and episclera; may be subtle and require retroillumination or high magnification
• Inferior and nasal bulbar conjunctival injection more prominent than superior
• Lissamine green staining of the inferior and nasal conjunctiva in moderate–severe disease (Grade 2–3 on Oxford Staining Scale)
• Reduced tear meniscus height (<0.2 mm) on slit-lamp assessment

Corneal Signs (by severity)

• Mild (Kazin Grade 1–2): Inferior punctate epithelial keratitis (PEK) staining with sodium fluorescein; pattern confined to inferior interpalpebral zone; may be subtle and require cobalt blue filter at high magnification
• Moderate (Kazin Grade 2–3): Peripheral subepithelial infiltrates (typically inferior); microvesiculation; peripheral corneal vascularisation beginning at inferior limbus; corneal staining extending centrally
• Severe (Kazin Grade 3–4): Central corneal infiltrates and keratitis; stromal haze; persistent epithelial defects; active or established inferior corneal neovascularisation; progressive corneal scarring
• Advanced: Corneal thinning (pachymetry <500 µm at affected area); irregular corneal surface on topography; significantly reduced BCVA
• Decreased corneal sensitivity (aesthesiometry) in chronic keratitis — differentiates from herpetic disease (severe reduction) but reduction does occur in rosacea

Tear Film Abnormalities

• TBUT: Typically <5 s in moderate–severe disease; <10 s in mild disease (normal ≥10 s); non-invasive TBUT (NIBUT) on Keratograph 5M often <7 s
• Schirmer's test: Often <10 mm/5 min (borderline); severely deficient (<5 mm/5 min) in aqueous-deficient component; combined evaporative and aqueous deficiency is common
• Lipid layer evaluation: Reduced lipid layer grade on interferometry (Tearscope or Lipiview); grade 1–2 (thin, grey pattern) typical vs normal grade 3–5
• Tear osmolarity: Elevated (>308 mOsm/L or intereye asymmetry >8 mOsm/L) reflecting tear film hyperosmolarity
• Meibography (infrared): Partial or complete meibomian gland dropout; gland tortuosity; gland shortening — correlates with severity and duration

Ocular Complications

• Progressive keratitis with corneal infiltration: Begins as inferior peripheral subepithelial infiltrates; may progress centrally with stromal involvement in severe or untreated disease
• Corneal neovascularisation: Characteristically affects the inferior cornea (reflecting inferior lid-cornea contact zone); superficial pannus formation in early disease; deep stromal vessels in advanced disease; risk of lipid keratopathy overlying the vascular arcade
• Persistent epithelial defects: Failure of re-epithelialisation due to combined MMP-mediated barrier disruption, neurotrophic corneal changes, and inadequate lubrication; risk of secondary microbial superinfection
• Corneal scarring and irregular astigmatism: Subepithelial and stromal scarring in the visual axis causes irregular astigmatism on topography (SimK asymmetry, saggital elevation changes); significantly reduces BCVA and spectacle-corrected acuity
• Decreased corneal sensation: Neurotrophic changes from chronic keratitis; reduced Cochet-Bonnet aesthesiometry values; increases risk of undetected trauma and delayed healing
• Secondary microbial keratitis: Staphylococcus aureus (including MRSA in immunocompromised or corticosteroid-treated patients) and coagulase-negative Staphylococci are most common pathogens; occurs on a background of compromised ocular surface defence
• Meibomian gland atrophy (irreversible end-stage): Complete glandular dropout on meibography; permanent loss of lipid secretory function; refractory evaporative dry eye even with aggressive treatment
• Severe dry eye with xerophthalmus: Rare in well-managed patients; seen in neglected or treatment-refractory disease; associated with squamous metaplasia and conjunctival keratinisation

Vision-Threatening Complications

• Corneal thinning: Peripheral (inferior) corneal thinning in established vascular pannus; central thinning in severe keratitis; assess with AS-OCT or Scheimpflug pachymetry
• Corneal ectasia: Rare but reported; irregular topography and thinning may mimic early keratoconus; contact lens fitting is challenging and may be contraindicated in active disease
• Corneal perforation: Exceedingly rare; occurs only in the context of severe untreated keratitis with corneal thinning; requires urgent ophthalmological management with tectonic grafting
• Lipid keratopathy: Secondary to corneal neovascularisation; yellowish-white stromal lipid deposition along vascular arcade; can significantly reduce BCVA

Quality of Life Impact

• Chronic discomfort and symptom burden disproportionate to clinical signs in many patients
• Visual disability from tear instability (fluctuating acuity), corneal scarring, or irregular astigmatism
• Psychological impact — anxiety, depression, and social isolation from chronic condition and facial appearance
• Reduced occupational productivity, particularly in screen-dependent workers (digital eye strain compounding symptoms)
• Ocular discomfort impacts sleep quality and morning functioning (symptoms worse on waking due to nocturnal lid closure effects on meibomian gland secretion)

Associated Systemic Conditions

• Cutaneous rosacea: Present in 50-90% of ocular rosacea cases
• Gastrointestinal tract involvement: Increased prevalence of H. pylori, IBS, GERD
• Cardiovascular associations: Some studies show increased cardiovascular risk and hypertension
• CNS involvement: Rare reports of migraine headaches (controversial)

Systemic Workup Indications

Systemic evaluation may be considered for:

• New-onset rosacea without prior cutaneous manifestations
• Persistent GI symptoms or diarrhea
• Severe systemic symptoms warranting H. pylori or other investigation

Clinical History

• Duration and onset of ocular symptoms
• Presence or absence of cutaneous rosacea
• Identified trigger factors (heat, stress, dietary)
• Impact on daily functioning and quality of life
• Previous treatments and responses
• Associated systemic symptoms (GI upset, flushing)

Clinical Examination

Standardized Diagnostic Criteria

AAO (American Academy of Ophthalmology) Diagnostic Criteria for Ocular Rosacea:

1. Lifestyle Modifications & Trigger Avoidance (Within Singapore Optometry Scope)

• Sun protection: Broad-spectrum sunscreen (SPF ≥30), UV-blocking sunglasses
• Avoid known triggers: Extreme temperatures, spicy foods, alcohol, vasodilating substances
• Stress management: Relaxation techniques, exercise, counseling
• Environmental control: Humidifiers in dry conditions, avoid wind exposure

2. Ocular Surface Management — First-line (Within Singapore Optometry Scope)

3. Topical Pharmacotherapy (Medical Referral Required — Beyond Singapore Optometry Scope)

4. Systemic Pharmacotherapy (Ophthalmology/Medical Referral Required — Beyond Singapore Optometry Scope)

5. Procedural Interventions (Physician-Supervised — Beyond Singapore Optometry Scope)

• Intense pulsed light (IPL): Reduces conjunctival telangiectasia and lid margin erythema
• Radiofrequency ablation: Emerging technology for meibomian gland restoration
• Punctal plugs: For aqueous-deficient dry eye component

Visual Prognosis

• Generally favorable: Most patients retain good visual acuity with appropriate management
• Excellent: If diagnosed early and treated aggressively before corneal scarring
• Good: For mild to moderate disease with compliance
• Guarded: In advanced disease with significant keratitis or scarring

Disease Course

• Chronic, relapsing-remitting course typical
• Spontaneous remissions may occur (less common)
• Progression is usually slow but can be variable
• Worsening with aging is common

Factors Affecting Prognosis

Conditions to Distinguish from Ocular Rosacea

Key References (NLM Format)

1. Browning DJ, Proia AD. Ocular rosacea. Surv Ophthalmol. 1986;31(3):145–158.
2. Akpek EK, Merchant A, Pinar V, Foster CS. Ocular rosacea: patient characteristics and follow-up. Ophthalmology. 1997;104(11):1863–1867.
3. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584–587.
4. Ghanem VC, Mehra N, Wong S, Mannis MJ. The prevalence of ocular signs in acne rosacea: comparing patients from ophthalmology and dermatology clinics. Cornea. 2003;22(3):230–233.
5. Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol. 2013;69(6 Suppl 1):S15–S26.
6. Vieira AC, An JA, Zoroquiain P, et al. Ocular changes in patients with cutaneous rosacea treated with systemic doxycycline. Arq Bras Oftalmol. 2012;75(5):363–369.
7. van Zuuren EJ. Rosacea. N Engl J Med. 2017;377(18):1754–1764.
8. Schechter BA, Katz RS, Friedman LS. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther. 2009;26(6):651–659.
9. Papageorgiou P, Clayton W, Norwood S, Chopra S, Rustin M. Treatment of rosacea with intense pulsed light: significant improvement and long-lasting results. Br J Dermatol. 2008;159(3):628–632.
10. Mathers WD, Shields WJ, Sachdev MS, Petroll WM, Jester JV. Meibomian gland morphology and tear osmolarity: changes with Accutane therapy. Cornea. 1991;10(4):286–290.
11. Liang L, Liu Y, Ding X, et al. Significant correlation between meibomian gland loss and the presence of Demodex in patients with rosacea. Br J Ophthalmol. 2018;102(8):1098–1101.
12. Baudouin C, Aragona P, Messmer EM, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf. 2013;11(4):246–258.
13. Pflugfelder SC, de Paiva CS. The pathophysiology of dry eye disease: what we know and future directions for research. Ophthalmology. 2017;124(11S):S4–S13.
14. Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011;52(4):1922–1929.
15. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–283.
16. Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438–510.
17. van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L. Interventions for rosacea. Cochrane Database Syst Rev. 2015;(4):CD003262.
18. Optometrists and Opticians Board, Ministry of Health Singapore. Guidelines on the scope of optometry practice in Singapore. Singapore: MOH; 2022.

Clinical Guidelines & Consensus Statements

• National Rosacea Society Expert Committee. Standard classification of rosacea (2002; updated 2018 phenotype-based approach)
• American Academy of Dermatology (AAD). Rosacea: Diagnosis and treatment guidelines (updated 2021)
• American Academy of Ophthalmology (AAO). Preferred Practice Pattern: Blepharitis (2023)
• Tear Film & Ocular Surface Society (TFOS). DEWS II Workshop Reports — Pathophysiology, Definition, and Management (2017)
• TFOS International Workshop on Meibomian Gland Dysfunction (2011)

Patient Education Resources

• National Rosacea Society (nrs.org): Patient guides, trigger tracking tools, research updates
• American Academy of Dermatology (aad.org): Patient education materials on rosacea
• American Academy of Ophthalmology (aao.org): Resources on ocular manifestations and management
• Singapore National Eye Centre (snec.com.sg): Local ophthalmology resources and patient information